CLICK BUTTON to REGISTER

CLICK to REGISTER Exit Disclaimer

Metformin Pharmacogenomics

June 6–7, 2012 Metformin Pharmacogenomics

Registration Link

http://www.scgcorp.com/metforminPGx2012 Exit Disclaimer

Event Details

Meeting Abstract
The incidence of type 2 diabetes and its costs to the healthcare system are continuing to rise. Despite the availability of at least five drug classes for the treatment of type 2 diabetes, metformin remains the most widely used first-line pharmacotherapy. As medicine enters the genomic era, there is the opportunity to understand the genetics underlying inter-individual variation in pharmacological responses of metformin to achieve safer, more effective treatment in those who respond, deploy alternative therapies in those who do not, and develop new comparable agents. The goals of this workshop are to review the state of the science on metformin pharmacogenomics, discuss the scientific and clinical hurdles to furthering our knowledge of the variations in patient responses to metformin, and consider how to utilize effectively this increased understanding to improve patient outcomes in both the academic and private sectors. The workshop also will explore how the potential effectiveness of metformin for additional indications such as diabetes and cancer prevention, polycystic ovarian disease, and Alzheimer’s disease can both aid and be aided by the understanding of metformin pharmacogenomics.

Agenda

AGENDA

Chairs
Workshop Chairs:  Jose Florez, Kathleen Giacomini, and Alan Shuldiner
NIDDK Organizers:  Aaron Pawlyk, Catherine McKeon, Myrlene Staten, and Arthur Castle

Wednesday, June 6, 2012

On your own for dinner.

   
Thursday, June 7, 2012
8:00 a.m. Welcome and Orientation
Griffin Rodgers, NIDDK
Aaron Pawlyk, NIDDK
Session I: Understanding the Uses and Responses of Metformin
Moderator: Alan Shuldiner, University of Maryland
8:00 a.m. Welcome and Orientation
8:15 a.m. Introduction to Metformin and Its Clinical Use
Ronald Goldberg, University of Miami Miller School of Medicine
8:45 a.m. Where Are We With Metformin PGx and Where Can We Go?
Ewan Pearson, University of Dundee, United Kingdom
9:30 a.m. Metformin Pharmacogenomics:  Ethnicity and Transporter Gene x Gene Interactions
Kathleen Giacomini, University of California, San Francisco
10:00 a.m. Pharmacometabolomics and Its Integration With Pharmacogenomics
Rima Kaddurah-Daouk, Duke University Medical Center
10:30 a.m. Break
10:45 a.m.

Guided Discussion Panel
Multitudes of Metformin Populations:  Type 2 Diabetes (T2D)– Prevention, Treatment, Pediatrics, Cancer, Aging, Alzheimer’s Disease, and Polycystic Ovarian Disease

10:45 a.m.

Challenges Outside of T2D:  Diabetes Prevention and Gene Variants
Jose Florez, Massachusetts General Hospital

11:00 a.m. Panel Discussion
Jose Florez, Massachusetts General Hospital (Prevention)
Phil Zeitler, Children's Hospital Colorado (Pediatric)
Corrine Welt, Massachusetts General Hospital (Polycystic Ovary Syndrome)
Pamela Goodwin, Mount Sinai Hospital (Breast Cancer)
11:30 a.m. Lunch – grab it and come back!
   
Session II: Health Care Systems and Information Management
Moderator: Toni Pollin, University of Maryland School of Medicine
12:15 p.m. The eMERGING Role of Health-care Systems in Pharmacogenomics
Rex Chisholm, Northwestern University
12:35 p.m. Pharmacy Benefit Manager-based Pharmacogenomics and Personalized Medicine Approaches
Eric Stanek, Medco Health Solutions, Inc.
12:55 p.m. Genetic Architecture of Drug Efficacy and Toxicity – Implications For Discovery and Clinical Implementation
Robert Plenge, Harvard Medical School/Brigham and Women’s Hospital
   
Session III: Models of Collaboration
Moderator: Monique Hedderson, Kaiser Permanente Northern California
1:10 p.m. RIKEN Center for Genomic Medicine and Collaboration With the Pharmacogenomics Research Network
Michiaki Kubo, Center for Genomic Medicine, RIKEN, Japan
1:30 p.m. PharmGKB:  Lessons From Other Pharmacogenomics Efforts
Teri Klein, Stanford University
1:50 p.m. Toward Personalized Medicine in Diabetes:  A View From Pharma
Dawn Waterworth, GlaxoSmithKline
2:10 p.m. Past, Present, and Future NIH-funded Metformin Trials
David Nathan, Harvard Medical School/Massachusetts General Hospital
2:40 p.m.

Quick Objectives Overview for Breakout Sessions     
Aaron Pawlyk, NIDDK

2:45 p.m. Break
   
Session IV: Breakout sessions
3:00 p.m. Discussions of key scientific issues and next steps towards understanding the pharmacogenomics of the metformin response:
  1. Pharmacogenomics to Understand Metformin’s Mechanism and New Drug Target Discovery
    Chairs:  Jose Florez, Massachusetts General Hospital and Marc Reitman, NIDDK
  2. Scientific, Informatics, Collaborative, and Logistical Needs for Large-scale Validation of Metformin Pharmacogenomics
    Chairs: Kathy Giacomini, University of California, San Francisco and Monique Hedderson, Kaiser Permanente Northern California
  3. Challenges to Translating Metformin Pharmacogenomics Into the Clinic for Multiple Endpoints and in Diverse Ethnic Backgrounds
    Chairs: Alan Shuldiner, University of Maryland and Eric Stanek, Medco Health Solutions, Inc.
3:45 p.m. Break; Meeting Chairs prepare summary
4:00 p.m. Presentations of Discussions at Breakouts and Moderated Discussion
Moderators:  External Scientific Chairs
4:45 p.m. Adjournment
   

Organizers Draft Workshop Report.

[Back to Top]

Contact

For questions concerning program content, contact:

Aaron Pawlyk, Ph.D.
National Institute of Diabetes and Digestive and Kidney Diseases
Phone:  (301) 451-7299
Email:  aaron.pawlyk@nih.gov

For questions concerning meeting logistics, contact:

John Hare, M.S., CMP
The Scientific Consulting Group, Inc.
Phone:  (301) 670-4990
Email:  jhare@scgcorp.com

[Back to Top]

Registration and Logistics

LOCATION
The Mayflower Renaissance Washington, DC Hotel
1127 Connecticut Avenue N.W.
Washington, DC  20036-4301
Telephone:  (202) 347-3000 or (800) 468-3571
Website:  http://www.marriott.com/hotels/travel/wassh-renaissance-mayflower-hotel/ Exit Disclaimer
(More hotel information can be obtained from this website.)

DRIVING DIRECTIONS
From a specific destination, you may enter starting point here:  http://www.marriott.com/hotels/maps/travel/wassh-the-mayflower-renaissance-washington-dc-hotel/ Exit Disclaimer.

From Baltimore/Washington International Thurgood Marshall Airport (BWI)
Head northeast on Elm Road toward Governor Harry R. Hughes Drive. Continue onto I-195 West. Take Exit 2B for MD-295 South/Baltimore/Washington Parkway toward Washington. Merge onto MD-295 South. Take the exit onto US-50 West toward Washington. Take the exit toward Ft. Lincoln Drive/South Dakota Avenue. Keep left at the fork and follow signs for South Dakota Avenue. Make a slight right onto South Dakota Avenue N.E. Take a slight left to stay on South Dakota Avenue N.E. Turn right onto Vista Street N.E. Take the first left onto Central Avenue N.E. Turn left onto Rhode Island Avenue N.E. Turn left onto 11th Street N.W. Turn right onto K Street N.W. Turn right onto Connecticut Avenue N.W. The hotel will be on the right.

From Washington Dulles International Airport (IAD)
Follow the signs to Interstate 66 East to Washington. Follow I-66 to the Theodore Roosevelt Bridge (US Route 50). Take the E Street exit off of the bridge. Turn left onto 17th Street; 17th Street will turn into Connecticut Avenue. The hotel will be on the right side of Connecticut Avenue.

From Ronald Reagan Washington National Airport (DCA)
Follow the signs to Washington DC (George Washington Parkway). Take the I-395/Route 1 North exit (which is the 14th Street Bridge). Merge to the far left lane and follow the signs for 14th Street. Follow 14th Street for approximately 10 blocks and make a left onto K Street. Enter into the right service lane on K Street. Make a right onto Connecticut Avenue; the hotel will be on the right.

METRO INFORMATION
The Metro system is a clean and reliable mode of transportation. It operates from 5:00 a.m. to 12:00 midnight on Monday through Thursday; 5:00 a.m. to 3:00 a.m. on Fridays; 7:00 a.m. to 3:00 a.m. on Saturdays; and 7:00 a.m. to 12:00 midnight on Sundays. Each passenger must buy a farecard to travel in the system. Guides for purchasing farecards are posted on the vending machines in each station. Each Metro car features a complete color-coded map of the system. Station attendants on duty at each station can provide additional information on request. A map of the system is available at:  http://www.wmata.com/rail/maps/map.cfm Exit Disclaimer.

From Ronald Reagan Washington National Airport, take the Blue Line toward Largo Town Center and exit at the Farragut West Station 17th Street Exit. Head East on I Street N.W. for 100 feet and turn left onto 17th Street N.W. Continue onto Connecticut Avenue N.W. The hotel will be on the right in 0.1 miles.

SHUTTLES
SuperShuttle offers service to most hotels from Ronald Reagan Washington National Airport, Washington Dulles International Airport, and Baltimore/Washington International Thurgood Marshall Airport. The shuttle leaves on an as-needed basis between the hours of 5:30 a.m. and 11:00 p.m. During other times, arrangements for a shuttle can be made by calling 1-800-258-3826 from the airport, or visit their website at http://supershuttle.com Exit Disclaimer.

TAXIS
The taxi fare is approximately $18 from Ronald Reagan Washington National Airport, approximately $65 from Washington Dulles International Airport, and approximately $70 from Baltimore/Washington International Thurgood Marshall Airport.

PARKING INFORMATION
$45 overnight with in/out privileges.
$25 during the day, no in/out privileges.

[Back to Top]

  

  

    

Page last updated: June 06, 2012

General inquiries may be addressed to:
Office of Communications & Public Liaison
NIDDK, NIH
Bldg 31, Rm 9A06
31 Center Drive, MSC 2560
Bethesda, MD 20892-2560
USA
301.496.3583

The National Institutes of Health   Department of Health and Human Services   USA.gov is the U.S. government's official web portal to all federal, state, and local government web resources and services.  This website is certified by Health On the Net Foundation. Click to verify.